Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Slides:

Advertisements

Similar presentations

Margaret Tempero, M.D. Professor of Medicine University of California, San Francisco Debate: This house believes that FOLFIRINOX is the best treatment.

Advertisements

Discussant Slides: Title: Radiosensitivity Index Shows Promise for Predicting Outcomes with Adjuvant Radiation in Resected Pancreatic Cancer Patients Poster.

종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.

R3 이운주/Prof 맹치훈. Introduction Pancreatic adenocarcinoma is most lethal cancer, with a 5-year survival rate of less than 5%. Relapsed occurs in 80-85%

? miRNA profiling (primary vs recurrent) Between patients cohort (n=6)

Figure 2 Exosome composition

Figure 5 Schematic illustration of different clinical trial designs

Figure 4 Activation of clopidogrel via cytochrome P450

Figure 1 The epigenetic landscape mediates the interplay between stressors and renal dysfunction Figure 1 | The epigenetic landscape mediates the interplay.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Figure 1 Patients cured of HCV infection

Nat. Rev. Urol. doi: /nrurol

Figure 2 A stage-based approach to the treatment of NAFLD

Figure 1 Gut microorganisms at the intersection of several diseases

Figure 1 Worldwide incidence of CCA

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Figure 5 Exosomes for delivery of RNA interference therapeutics

Figure 1 Biosimilar development process

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 4 Oncogenic KRAS and inflammation

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Volume 155, Issue 2, Pages (August 2018)

Figure 4 Road to targeting mutant p53

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Exosomes with siRNAs targeting

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 1 Median coverage and distribution by

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 5 Chrononutrition in the liver

Figure 4 Diverse molecular mechanisms of long non-coding RNAs

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Treatment of Locally Advanced Pancreatic Cancer

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Overall survival in the IFCT trial comparing a single agent therapy arm (vinorelbine or gemcitabine) and the doublet carboplatin plus weekly paclitaxel.

Management of Advanced Pancreatic Adenocarcinoma

Figure 3 Examples of gene expression heterogeneity

Figure 2 Frequency and overlap of alterations

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 New therapeutic approaches in IBD with their specific targets

Figure 3 KRAS-driven intrinsic signalling pathways

Figure 5 Systems biological model of IBS

Altered Interphase Fluorescence in Situ Hybridization Profiles of Chromosomes 4, 8q24, and 9q34 in Pancreatic Ductal Adenocarcinoma Are Associated with.

Figure 2 Core molecular clock machinery

Nat. Rev. Urol. doi: /nrurol

Figure 1 Cancer stem cell plasticity and stem cell homeostasis in the gut Figure 1 | Cancer stem cell plasticity and stem cell homeostasis in the gut.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Volume 151, Issue 2, Pages (August 2016)

One potential implementation for the use of outlier kinase profiling and targeting for clinical management of pancreatic cancer in a precision medicine.

Presentation transcript:

Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.182 Figure 1 Selected advances in pancreatic ductal adenocarcinoma during 2017 Figure 1 | Selected advances in pancreatic ductal adenocarcinoma during 2017. Studies highlighted here include an integrated characterization of the molecular landscape of pancreatic ductal adenocarcinoma (PDAC) from The Cancer Genome Atlas (part a), which confirmed the existence of two subtypes based on molecular expression profiles with prognostic implications; a novel systemic delivery platform using inhibitory exosomes (iExosomes) to genetically target mutant KRAS in multiple preclinical PDAC models (part b); and a new standard of care, gemcitabine plus capecitabine, showed improved overall survival for the adjuvant therapy of resected PDAC (part c). lncRNA, long non-coding RNA; miRNA, microRNA; siRNA, small interfering RNA. Semaan, A. & Maitra, A. (2018) Rebooting pancreatic cancer knowledge and treatment options Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.182